In particular, the triple negative breast cancer, lacking of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), is resistant to therapies, and is associated with reduced survival for tumor recurrence and metastasis [26]. Here, ERBB2 is linked to triple-negative breast carcinoma.